Antithrombin Cambridge II (A384S): prevalence in patients of the Paris Thrombosis Study (PATHROS)
Copyright policy ) Véronique, Picard; Isabelle, Présot; Pierre-Yves, Scarabin; Martine, Aiach; Joseph, Emmerich; Martine, Alhenc-Gelas;
Antithrombin Cambridge II (A384S): prevalence in patients of the Paris Thrombosis Study (PATHROS)
To the editor: The antithrombin (AT) Cambridge II (A384S), which results from a nucleotide (nt) G > T substitution at position 13268 of the gene (numbering system from Olds et al[1][1]), is a variant associated with borderline or mildly reduced antithrombin heparin cofactor activity, but normal
Paris, Alanine, Case-Control Studies, Antithrombin III, Mutation, Serine, Humans, Thrombosis
Paris, Alanine, Case-Control Studies, Antithrombin III, Mutation, Serine, Humans, Thrombosis
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).10 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
citations
Citations provided by BIP!
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
Citations provided by BIP!popularityPopularity provided by BIP!
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
Popularity provided by BIP! 10
Average
Top 10%
Top 10%
